TIMI Study Finds New Class of Anti-Clotting Drug Reduced Bleeding Events Compared with Standard of Care in Patients with Atrial Fibrillation

The researchers found that abelacimab, a Factor XI inhibitor, at a dose of 150 mg monthly, significantly reduced bleeding compared to the standard-of-care anticoagulant, rivaroxaban.
Source: BWH News - Category: Hospital Management Source Type: news